[An open randomized comparative trial of efficacy and safety of selective alpha-adrenoblocker setegis (terazosin) in therapy of patients with chronic bacterial prostatitis].
An open randomized comparative trial of setegis (terazosine) has shown good subjective and objective results in patients with chronic bacterial prostatitis. The drug is well tolerated and produces insignificant side effects. It is also demonstrated that combined therapy with alpha-adrenoblockers is more effective that monotherapy with antibacterial drugs in patients with bacterial prostatitis.
Trapeznikova
M F
MF
Morozov
A P
AP
Dutov
V V
VV
Urenkov
S B
SB
Pozdniakov
K V
KV
Bychkova
N V
NV
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011472:Prostatitis / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome
D000317:Adrenergic alpha-Antagonists; D000900:Anti-Bacterial Agents; C041226:Terazosin; D011224:Prazosin